In most cases, FGFRL1 exhibits to promote the development and progression of tumors including bladder cancer, esophageal cancer, larynx carcinoma, lung cancer, ovarian cancer, and prostate cancer. Here, FGFRL1 is linked to urinary bladder carcinoma.